Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Federal Trade Commission
Teva
Healthtrust
US Army
UBS
Baxter
Julphar
Express Scripts

Generated: April 21, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MPI STANNOUS DIPHOSPHONATE

« Back to Dashboard

Clinical Trials for MPI STANNOUS DIPHOSPHONATE

Trial ID Title Status Sponsor Phase Summary
NCT00306046 18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone Completed FNRS (Belgium) N/A 18 F-fluoride Positron emission tomography (PET) is able to demonstrate and quantify the metabolic activity locally in the skeleton (1). This technique should, therefore, also be able to demonstrate a dramatic decrease in the metabolic activity in localized monostotic Paget’s disease lesions after therapy. In this condition, indeed, the usual biological markers may be unhelpful to assess the efficacy of therapy, because they are usually comprised in the normal range for single pagetic localizations, even before therapy (2). The main purpose of this trial is to assess the early and long term response of pagetic bone to bisphosphonate therapy.
NCT00306046 18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone Completed Université Catholique de Louvain N/A 18 F-fluoride Positron emission tomography (PET) is able to demonstrate and quantify the metabolic activity locally in the skeleton (1). This technique should, therefore, also be able to demonstrate a dramatic decrease in the metabolic activity in localized monostotic Paget’s disease lesions after therapy. In this condition, indeed, the usual biological markers may be unhelpful to assess the efficacy of therapy, because they are usually comprised in the normal range for single pagetic localizations, even before therapy (2). The main purpose of this trial is to assess the early and long term response of pagetic bone to bisphosphonate therapy.
NCT01240551 F-18 Sodium Fluoride in Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 Background: - Sodium fluoride (NaF) is a common compound that is found in various foods and can be used to increase bone strength. When this compound is added to a small dose of radiation (F-18), it collects in the bones, with higher amounts in areas where the bone is rapidly changing, such as the site of a healing fracture or a tumor. By giving F-18 NaF before a combined positron emission tomography/ computed tomography (PET/CT) scan, researchers hope to be able to better measure the changes in the bone that may indicate that a certain type of cancer (such as prostate cancer) has spread to the bones. Objectives: - To evaluate the effectiveness of F-18 NaF in imaging studies to measure bone tumors and their change over time and compare with clinical course, in individuals with prostate cancer. - To determine the smallest amount of change in the bone tumors that F-18 NaF can accurately measure. Eligibility: - Men at least 18 years of age who have been diagnosed with prostate cancer and have had imaging studies to determine whether the cancer has spread to their bones. Both patients with and without known bone involvement will be enrolled. Design: - Participants will be screened with a physical examination, medical history, and imaging studies, and will provide baseline blood samples to evaluate kidney function. - For the study, participants will have two F-18 NaF PET/CT scans on separate days for baseline. These repeat scans will be used to determine the amount of change that is due to the imaging process alone (i.e. not due to the disease getting better or worse. Participants will receive a dose of F-18 NaF intravenously, and will have PET/CT scanning over the body (mid ear to upper thighs) over 1 hour, the body followed by a complete whole-body PET/CT scan at approximately 2 hours after F-18 NaF injection. Participants will be watched closely for side effects from the F-18 NaF until the scans are done, and will be asked to drink plenty of water to void the F-18 NaF from the body after the scans. - As a followup study, participants will have two more F-18 NaF PET/CT scans, one 4 to 8 months after the first scans and then one 10 to 14 months after the first scans. Participants will provide additional blood samples before the followup scans.
NCT01317446 Effect of Mouthrinsing on Inflammation of the Gums. Completed Gaba International AG Phase 4 The purpose of this study is to determine whether rinsing with an amine fluoride/stannous flouride mouthrinse in addition to daily tooth brushing is more effective than tooth brushing alone.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for MPI STANNOUS DIPHOSPHONATE

Condition Name

Condition Name for MPI STANNOUS DIPHOSPHONATE
Intervention Trials
Gingivitis 5
Plaque 2
Dentin Sensitivity 2
Prostate Neoplasm 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for MPI STANNOUS DIPHOSPHONATE
Intervention Trials
Gingivitis 5
Hypersensitivity 4
Dentin Sensitivity 3
Prostatic Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for MPI STANNOUS DIPHOSPHONATE

Trials by Country

Trials by Country for MPI STANNOUS DIPHOSPHONATE
Location Trials
United States 57
Canada 5
Belgium 1
Switzerland 1
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for MPI STANNOUS DIPHOSPHONATE
Location Trials
Indiana 5
Nevada 4
Maryland 2
New Jersey 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for MPI STANNOUS DIPHOSPHONATE

Clinical Trial Phase

Clinical Trial Phase for MPI STANNOUS DIPHOSPHONATE
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for MPI STANNOUS DIPHOSPHONATE
Clinical Trial Phase Trials
Completed 12
Not yet recruiting 4
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for MPI STANNOUS DIPHOSPHONATE

Sponsor Name

Sponsor Name for MPI STANNOUS DIPHOSPHONATE
Sponsor Trials
GlaxoSmithKline 6
National Cancer Institute (NCI) 3
Procter and Gamble 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for MPI STANNOUS DIPHOSPHONATE
Sponsor Trials
Industry 14
Other 12
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Deloitte
US Army
Mallinckrodt
Fish and Richardson
McKinsey
AstraZeneca
McKesson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.